Buy Tesamorelin (10mg)

Tesamorelin Description

Tesamorelin is a synthetic peptide analogue of GHRH with a trans-3-hexenoic acid moiety anchored at the N-terminus of its 44-amino acid sequence, providing enhanced stability compared to endogenous GHRH. The compound stimulates pituitary secretion of growth hormone and subsequently increases insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels in laboratory models.

Peptide Information

Peptide Structure

Source: PubChem

Lyophilized Peptides:

These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.

Product Usage:

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only.  This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Tesamorelin Research

Tesamorelin is a stabilized GHRH analogue that exhibits regulatory effects on metabolism through its influence on the growth hormone/IGF-1 axis. In research models, the compound demonstrates the capacity to affect visceral adipose tissue metabolism, triglyceride levels, and lipid profiles through combined anabolic and lipolytic mechanisms without significant impact on glucose homeostasis in controlled settings.

Efficacy in Reducing Visceral Adipose Tissue

Tesamorelin has been shown to effectively reduce visceral adipose tissue (VAT) in people with HIV-associated lipodystrophy. In two well-designed trials, tesamorelin significantly decreased VAT without affecting subcutaneous adipose tissue to a clinically significant extent. This reduction was maintained over a longer term in patients who continued therapy, although VAT reaccumulated upon discontinuation¹.

Additionally, tesamorelin improved body composition measures such as trunk fat and waist circumference, and enhanced body image parameters¹.

Impact on Non-Alcoholic Fatty Liver Disease (NAFLD)

Tesamorelin has demonstrated promising results in reducing liver fat and preventing fibrosis progression in HIV-associated NAFLD. A randomized placebo-controlled trial showed that tesamorelin reduced hepatic fat fraction and improved fibrosis-related gene scores, indicating a potential therapeutic role in managing NAFLD in this population².

The peptide modulated hepatic gene pathways, increasing oxidative phosphorylation and decreasing inflammation-related gene expressions².

Effects on Fat Quality

Beyond reducing fat quantity, tesamorelin has been found to improve fat quality. In trials assessing fat density, tesamorelin increased both VAT and subcutaneous adipose tissue density, suggesting an enhancement in fat quality independent of quantity changes³.

Cardiovascular and Metabolic Outcomes

Tesamorelin’s impact on cardiovascular disease (CVD) risk has been explored, with findings indicating a modest reduction in 10-year atherosclerotic CVD risk scores. This reduction was primarily driven by decreases in total cholesterol, even among participants on lipid-lowering therapies⁴.

Furthermore, tesamorelin was well-tolerated, with no significant differences in glucose parameters observed between treatment and placebo groups¹.

Neurocognitive and Other Health Implications

While tesamorelin reduced waist circumference, its effects on neurocognitive impairment in abdominally obese subjects with HIV were not significantly different from standard care, suggesting limited cognitive effects⁵.

However, the peptide’s ability to increase insulin-like growth factor 1 (IGF-1) levels may have other experimental research applications worth exploring further⁵.

References

1. Falutz, J., Mamputu, J., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.. The Journal of clinical endocrinology and metabolism, 95 9, 4291-304 . https://doi.org/10.1210/jc.2010-0490.
2. Fourman, L., Billingsley, J., Agyapong, G., Sui, S., Feldpausch, M., Purdy, J., Zheng, I., Pan, C., Corey, K., Torriani, M., Kleiner, D., Hadigan, C., Stanley, T., Chung, R., & Grinspoon, S. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5. https://doi.org/10.1172/jci.insight.140134.
3. Lake, J., La, K., Erlandson, K., Adrian, S., Yenokyan, G., Scherzinger, A., Dubé, M., Stanley, T., Grinspoon, S., Falutz, J., Mamputu, J., Marsolais, C., McComsey, G., & Brown, T. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 35, 1395 – 1402. https://doi.org/10.1097/QAD.0000000000002897.
4. Grinspoon, S., Fourman, L., Stanley, T., McGary, C., Benkeser, D., & Cash, R. (2025). P-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis. Open Forum Infectious Diseases, 12. https://doi.org/10.1093/ofid/ofae631.633.
5. Ellis, R., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R., Lee, D., & Sattler, F. (2025). Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.. The Journal of infectious diseases. https://doi.org/10.1093/infdis/jiaf012.

Tesamorelin (260400)

Tesamorelin (12031)

Endotoxin Tesamorelin

Tesamorelin (251539)

Tesamorelin (251539E)

Tesamorelin

Tesamorelin BL-ENDO-250409-005

Tesamorelin(10166)

Tesamorelin(10174)

×

Disclaimer: For Research Purposes Only

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides. . .